Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-delta5NSP3
The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.
1. A pharmaceutical composition comprising CHIKV-Δ5nsP3 particles, wherein said composition comprises
(i) at least 10 3 CHIKV-Δ5nsP3 particles which express an E2 structural protein as defined by the amino acid sequence of SEQ ID NO: 2 and;
(ii) 1-70% CHIKV-Δ5nsP3 particles which express an E2 structural protein having one to ten mutations compared with the amino acid sequence of SEQ ID NO: 2.
2. The pharmaceutical composition according to claim 1 , wherein the CHIKV-Δ5nsP3 particles of (ii) express an E2 structural protein having no more than 9, 8, 7, 6, 5 or 4 mutations compared with the amino acid sequence of SEQ ID NO: 2.
3. The pharmaceutical composition according to claim 1 , wherein the CHIKV-Δ5nsP3 particles of (ii) express an E2 structural protein having no more than three mutations compared with the amino acid sequence of SEQ ID NO: 2.
4. The pharmaceutical composition according to claim 1 , wherein the CHIKV-Δ5nsP3 particles of (ii) express an E2 structural protein having one or two mutations compared with the amino acid sequence of SEQ ID NO: 2.
5. The pharmaceutical composition according to claim 1 , wherein said one to ten mutations are selected from mutations which affect the immunogenicity of the CHIKV-Δ5nsP3 particles and mutations which do not affect the immunogenicity of the CHIKV-Δ5nsP3 particles.
6. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition comprises up to 3×10 4 CHIKV-Δ5nsP3 particles expressing the E2 structural protein as defined by the amino acid sequence of SEQ ID NO: 2.
7. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition comprises up to 10 5 CHIKV-Δ5nsP3 particles expressing the E2 structural protein as defined by the amino acid sequence of SEQ ID NO: 2.
8. The pharmaceutical composition according to claim 1 , wherein said pharmaceutical composition comprises 1-50% of the CHIKV-Δ5nsP3 particles which express an E2 structural protein having one to ten mutations with respect to the amino acid sequence of SEQ ID NO: 2.
9. The pharmaceutical composition of claim 8 , wherein said pharmaceutical composition comprises 5-30% of the CHIKV-Δ5nsP3 particles which express an E2 structural protein having one to ten mutations with respect to the amino acid sequence of SEQ ID NO: 2.
10. The pharmaceutical composition according to claim 1 , wherein the CHIKV-Δ5nsP3 particles of (i) comprise an RNA genome corresponding to the DNA sequence of SEQ ID NO: 1.
11. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition induces neutralizing antibodies against CHIKV-Δ5nsP3 in a mouse immunized with said pharmaceutical composition resulting in a serum comprising said neutralizing antibodies, and wherein said serum neutralizes Chikungunya virus (CHIKV) infection of Vero cells by at least 80% in an in vitro neutralization assay at a 1:80 serum dilution.
12. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition induces neutralizing antibodies against CHIKV-Δ5nsP3 in a mouse immunized with said pharmaceutical composition resulting in a serum comprising said neutralizing antibodies, and wherein said serum neutralizes Chikungunya virus (CHIKV) infection of Vero cells by at least 90% in an in vitro neutralization assay at a 1:80 serum dilution.
13. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition induces neutralizing antibodies against CHIKV-Δ5nsP3 in a mouse immunized with said pharmaceutical composition resulting in a serum comprising said neutralizing antibodies, and wherein said serum neutralizes Chikungunya virus (CHIKV) infection of Vero cells by at least 95% in an in vitro neutralization assay at a 1:80 serum dilution.
14. The pharmaceutical composition according to claim 1 , which is obtained or obtainable by production of CHIKV-Δ5nsP3 particles in Vero cells, wherein said production comprises passaging CHIKV-Δ5nsP3 particles comprising an RNA genome corresponding to the DNA sequence of SEQ ID NO: 1 on Vero cells in culture less than five times.
15. The pharmaceutical composition according to claim 14 , wherein said CHIKV-Δ5nsP3 particles are passaged on Vero cells in culture at most three times.
16. The pharmaceutical composition according to claim 1 , wherein said pharmaceutical composition is a one-shot pharmaceutical composition.
17. The pharmaceutical composition according to claim 1 , wherein said pharmaceutical composition is a vaccine.
18. The pharmaceutical composition according to claim 17 , wherein said pharmaceutical composition is in a lyophilized form.
19. The pharmaceutical composition according to claim 17 , wherein the pharmaceutical composition is formulated for subcutaneous administration.
20. A method of protection against disease caused by Chikungunya virus in a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition according to claim 1 .
21. The method according to claim 20 , wherein the subject is a human subject.
22. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition comprises a pharmaceutically acceptable excipient.